Compare LRE & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LRE | ALUR |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 18.9M |
| IPO Year | 2023 | N/A |
| Metric | LRE | ALUR |
|---|---|---|
| Price | $1.29 | $1.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.25 |
| AVG Volume (30 Days) | 7.7K | ★ 58.2K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.27 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $130,601,512.00 | $17,208,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.47 |
| P/E Ratio | $3.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $1.02 |
| 52 Week High | $2.97 | $16.81 |
| Indicator | LRE | ALUR |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 35.76 |
| Support Level | $1.26 | $1.29 |
| Resistance Level | $1.45 | $1.48 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 16.22 | 9.18 |
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.